[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP0737471A3 - Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue - Google Patents

Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue Download PDF

Info

Publication number
EP0737471A3
EP0737471A3 EP96400513A EP96400513A EP0737471A3 EP 0737471 A3 EP0737471 A3 EP 0737471A3 EP 96400513 A EP96400513 A EP 96400513A EP 96400513 A EP96400513 A EP 96400513A EP 0737471 A3 EP0737471 A3 EP 0737471A3
Authority
EP
European Patent Office
Prior art keywords
earth metal
alkaline earth
tnf
metal salts
obtained therefrom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96400513A
Other languages
German (de)
English (en)
Other versions
EP0737471A2 (fr
Inventor
Lionel Breton
Olivier De Lacharriere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9504265A external-priority patent/FR2732600B1/fr
Priority claimed from FR9504267A external-priority patent/FR2732601B1/fr
Priority claimed from FR9504268A external-priority patent/FR2732602B1/fr
Priority claimed from FR9504264A external-priority patent/FR2732599B1/fr
Application filed by LOreal SA filed Critical LOreal SA
Publication of EP0737471A2 publication Critical patent/EP0737471A2/fr
Publication of EP0737471A3 publication Critical patent/EP0737471A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/005Preparations for sensitive skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention se rapporte à l'utilisation d'un sel d'un métal alcalino-terreux dans une composition cosmétique, pharmaceutique, vétérinaire et/ou dermatologique, pour traiter notamment les peaux sensibles. Elle se rapporte en outre à l'utilisation d'un sel d'un métal alcalino-terreux pour prévenir et/ou lutter contre la rosacée et/ou les irritations cutanées et/ou les dartres et/ou les érythèmes pudiques et/ou les sensations dysesthésiques et/ou les sensations d'échauffement et/ou les prurits de la peau et/ou des muqueuses. Le sel est en particulier le nitrate ou le chlorure de strontium.
EP96400513A 1995-04-10 1996-03-12 Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue Ceased EP0737471A3 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
FR9504265A FR2732600B1 (fr) 1995-04-10 1995-04-10 Utilisation d'un sel d'un metal alcalino-terreux dans une composition cosmetique et/ou dermatologique et composition obtenue
FR9504267A FR2732601B1 (fr) 1995-04-10 1995-04-10 Utilisation d'un sel de metal alcalino-terreux pour le traitement des rougeurs cutanees d'origine neurogene
FR9504265 1995-04-10
FR9504264 1995-04-10
FR9504268A FR2732602B1 (fr) 1995-04-10 1995-04-10 Utilisation d'un sel d'un metal alcalino-terreux dans une composition cosmetique ou pharmaceutique pour traiter les prurits
FR9504264A FR2732599B1 (fr) 1995-04-10 1995-04-10 Utilisation de sels de metaux alcalino-terreux comme inhibiteurs de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
FR9504267 1995-04-10
FR9504268 1995-04-10
FR9510980 1995-09-20
FR9510980 1995-09-20

Publications (2)

Publication Number Publication Date
EP0737471A2 EP0737471A2 (fr) 1996-10-16
EP0737471A3 true EP0737471A3 (fr) 2000-12-06

Family

ID=27515606

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96400513A Ceased EP0737471A3 (fr) 1995-04-10 1996-03-12 Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue

Country Status (4)

Country Link
US (1) US5851556A (fr)
EP (1) EP0737471A3 (fr)
CA (1) CA2173689C (fr)
NO (1) NO323573B1 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
US7404967B2 (en) 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
FR2742054B1 (fr) * 1995-12-06 1998-01-09 Synthelabo Compositions pharmaceutiques contenant un agent anti-inflammatoire et des ceramides vegetales
US6406709B1 (en) 1997-05-29 2002-06-18 Nidaria Technology Ltd. Method for inhibiting nematocyst discharge
US6338837B1 (en) * 1997-05-29 2002-01-15 Nidaria Technology Ltd. Compositions and methods for inhibiting nematocyst discharge
FR2774285B1 (fr) * 1998-02-03 2001-06-15 Roche Posay Lab Pharma Utilisation d'une composition cosmetique pour le traitement et la prevention de la rosacee
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
DE60235989D1 (de) 2001-06-26 2010-05-27 Amgen Fremont Inc Antikörper gegen opgl
US20030059450A1 (en) 2001-09-24 2003-03-27 Maibach Howard I. Method and topical formulation for treating skin conditions associated with aging
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
US7081247B2 (en) * 2002-05-20 2006-07-25 Nidaria Technology Ltd. Composition and method for inhibiting polar capsule discharge and protecting a subject from nematocyst sting
US20030232094A1 (en) * 2002-06-12 2003-12-18 Fuller Peter E. Composition and method for the treatment of skin irritations
US6943197B2 (en) 2002-06-21 2005-09-13 Howard I. Maibach Topical administration of pharmacologically active bases in the treatment of inflammatory dermatoses
US6821523B2 (en) * 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
WO2004011017A1 (fr) * 2002-07-31 2004-02-05 Himalayan International Institute Of Yoga Science And Philosophy Solutions d'irrigation nasale et procedes d'utilisation associes
DK1556020T3 (da) 2002-08-12 2009-06-22 Birkir Sveinsson Anvendelse af CGRP-antagonistforbindelser til behandling af psoriasis
EP1578782A4 (fr) 2002-12-30 2007-09-12 Amgen Inc Polytherapie a facteurs costimulants
US20070053994A1 (en) * 2003-03-27 2007-03-08 Egil Jellum Anti-inflammatory treatment
EP1622630B1 (fr) * 2003-05-07 2012-08-29 Osteologix A/S Composition contenant entre autres du strontium pour la prophylaxie et/ou le traitement de pathologies des cartilages et/ou des os
PL1745791T3 (pl) 2003-05-07 2013-11-29 Osteologix As Leczenie chorób chrząstki/kości za pomocą rozpuszczalnych w wodzie soli strontu
KR20060014433A (ko) * 2003-06-04 2006-02-15 에버사이츠, 엘엘씨 신규의 피부의학 조성물
DE10347824B4 (de) * 2003-10-10 2011-08-11 Lach, Hans-Joachim, Dr., 79331 Pharmazeutische oder kosmetische Zusammensetzung zur Behandlung der Haut
ES2342461T3 (es) * 2003-10-17 2010-07-07 Oy Neurofood Ab Agente de estroncio no radiactivo para tratar el cancer.
US7258875B2 (en) * 2003-12-04 2007-08-21 Chiou Consulting, Inc. Compositions and methods for topical treatment of skin infection
US20080167513A1 (en) * 2004-02-26 2008-07-10 Osteologlx A/S Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions
PT1732575E (pt) * 2004-02-26 2011-03-23 Osteologix As Compostos que contêm o estrôncio para uso na prevenção ou tratamento de condições ósseas necróticas
FR2872047B1 (fr) * 2004-06-23 2007-06-15 Oreal Composition pour peaux sensibles associant cation mineral et probiotique(s)
MXPA06015184A (es) 2004-06-23 2007-11-22 Nestec Sa Procedimiento y composiciones utiles para prevenir y/o tratar pieles sensibles y/o secas.
US20060045858A1 (en) * 2004-08-26 2006-03-02 Fuller Peter E Composition and method for reducing harmful effects of ultraviolet radiation impinging on the skin
EP1731137A1 (fr) * 2005-06-08 2006-12-13 Nestec S.A. Composition cosmétique ou dermatologique pour peaux sèches et/ou sensibles
WO2006037922A1 (fr) * 2004-10-04 2006-04-13 L'oreal Composition cosmetique et/ou dermatologique pour peaux sensibles
EP1642570A1 (fr) 2004-10-04 2006-04-05 L'oreal Composition cosmétique et/ou dermatologique pour peaux sensibles
ES2525495T3 (es) * 2004-10-08 2017-07-26 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster del ácido fumárico
US7300649B2 (en) 2005-02-11 2007-11-27 Genepharm, Inc. Cosmetic and cosmeceutical compositions for restoration of skin barrier function
FR2889057B1 (fr) * 2005-08-01 2008-07-18 Oreal Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches
GB0517043D0 (en) * 2005-08-19 2005-09-28 York Pharma Plc Improvements in pharmaceutical compositions
ES2664421T3 (es) 2005-11-14 2018-04-19 Teva Pharmaceuticals International Gmbh Anticuerpo antagonista dirigido contra un péptido relacionado con el gen de la calcitonina
WO2007060381A1 (fr) * 2005-11-24 2007-05-31 Santosolve As Préparations contenant du strontium et leur application à des méthodes de traitement cosmétique
GB0617191D0 (en) * 2006-08-31 2006-10-11 York Pharma Plc Improvements in pharmaceutical compositions
WO2009006701A1 (fr) * 2007-07-12 2009-01-15 Peter O'gorman Médicament topique
FR2919501B1 (fr) * 2007-08-02 2010-12-31 Oreal Utilisation d'hesperidine ou de l'un de ses derives pour la prevention et/ou le traitement des peaux relachees
FR2920304B1 (fr) 2007-09-04 2010-06-25 Oreal Utilisation cosmetique de lysat bifidobacterium species pour le traitement de la secheresse.
FR2920305B1 (fr) 2007-09-04 2010-07-30 Oreal Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles.
MX2010002247A (es) * 2007-09-04 2010-05-17 Oreal Uso de una combinacion de hesperidina y de un microorganismo para influir en la funcion de barrera de la piel.
FI122450B (fi) * 2007-12-28 2012-01-31 Neurofood Ab Oy Koostumus steriilin inflammaation hoitoon
ES2689322T3 (es) 2008-03-04 2018-11-13 Teva Pharmaceuticals International Gmbh Métodos para tratar el dolor crónico
AU2008274908B2 (en) * 2008-07-11 2014-08-14 Whipbird Pain Relief Pty Ltd Topical medicament
EP2379063B2 (fr) 2009-01-09 2021-02-24 Fwp Ip Aps Formule pharmaceutique comportant un ou plusieurs esters d'acide fumarique dans une matrice erosive
FR2942719B1 (fr) 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
US8409628B2 (en) * 2010-02-04 2013-04-02 Penguin IP Holdings, Inc. Methods and compositions for oxygenation of skin to treat skin disorders
EP2530068A1 (fr) 2011-05-31 2012-12-05 Lacer, S.A. Nouveaux sels de strontium, leur synthèse et leur utilisation dans le traitement de l'ostéoporose
CA3026687A1 (fr) 2012-03-21 2013-09-26 Galleon Labs Llc Complexes contenant du strontium administre par voie topique pour le traitement de la douleur, du prurit et de l'inflammation
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3119431B1 (fr) 2014-03-21 2024-01-24 Teva Pharmaceuticals International GmbH Anticorps antagonistes dirigés contre le peptide lié au gène de la calcitonine et leurs procédés d'utilisation
WO2016060626A1 (fr) * 2014-10-16 2016-04-21 Geli̇şi̇m Maki̇na-Madenci̇li̇k-Mühendi̇sli̇k Ti̇c. Ve San. Ltd. Şti̇. Procédés et compositions pour prévenir et traiter l'hyperhidrose
WO2016130686A1 (fr) * 2015-02-11 2016-08-18 Cosmederm Bioscience, Inc. Composés de strontium stables à haute concentration et formulations pour application topique
FR3034667B1 (fr) * 2015-04-13 2018-09-07 Laboratoires Dermatologiques D'uriage Composition cosmetique et/ou dermatologique contre l'acne
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
PE20191148A1 (es) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh Tratamiento de la migrana refractaria
US11433119B2 (en) 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders
US10391121B2 (en) 2017-05-03 2019-08-27 BioPharmX, Inc. Magnesium chloride composition for dermatological use

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1072355A (en) * 1964-06-17 1967-06-14 Michael Collin Antiseptic and anti-pruretic solution containing camphor
US3519711A (en) * 1967-09-01 1970-07-07 Robert E Svigals Composition and method of treating pruritic conditions of the skin
US4477439A (en) * 1981-04-13 1984-10-16 Walter J. Monacelli Treatment of irritated and excoriated areas around the stoma of ostomy patients
EP0217975A1 (fr) * 1985-10-08 1987-04-15 Psori-Med Ag Mélange de sels pour le traitement du psoriasis et autres maladies de la peau
EP0451300A1 (fr) * 1990-04-10 1991-10-16 Romuald Dr. Kowalski Composition contenant une dispersion colloidale de sulfate de baryum
US5296476A (en) * 1989-09-08 1994-03-22 Henderson Esther G Skin care compositions
DE4315866C1 (de) * 1993-05-12 1994-05-05 Wogepharm Gmbh Äußerliche Zubereitungen zur Therapie von Hauterkrankungen mit Photosensibilisatoren
WO1996019184A1 (fr) * 1994-12-21 1996-06-27 Cosmederm Technologies Formulations et procedes pour diminuer l'irritation de la peau
WO1996019228A1 (fr) * 1994-12-21 1996-06-27 Cosmederm Technologies Formulations et procedes pour diminuer l'irritation de la peau
WO1996019182A1 (fr) * 1994-12-21 1996-06-27 Cosmederm Technologies Formulations et procedes pour diminuer l'irritation de la peau

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE35991B1 (en) * 1971-01-22 1976-07-21 Comprehensive Pharmaceuticals Improvements in or relating to the treatment of diseases of the skin and mucosa
US3772431A (en) * 1972-09-21 1973-11-13 W Mlkvy Effervescent mouthwash tablet
US3888976A (en) * 1972-09-21 1975-06-10 William P Mlkvy Zinc and strontium ion containing effervescent mouthwash tablet
JPS58501675A (ja) * 1981-10-09 1983-10-06 フエ−リング・ア−ベ− 物質p「きつ」抗質からなる薬材
IT1214611B (it) * 1985-05-22 1990-01-18 Schiena Ricerche Composti per uso cosmetico dermatologico e relative composizioni.
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
US4735802A (en) * 1986-05-05 1988-04-05 Le Bich N Topical dermatological composition and method of treatment
US4986981A (en) * 1986-07-07 1991-01-22 Den Mat Corporation Toothpaste having low abrasion
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
SE8701372L (sv) * 1987-04-02 1988-10-03 Boliden Ab Foerfarande och medel foer konservering av hoe
DE3929411A1 (de) * 1988-09-22 1990-03-29 Siegfried Natterer Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
CA2014201A1 (fr) * 1989-04-26 1990-10-26 Albemarle Corporation Oxydes trialkylamines solides non hydroscopiques
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
FR2662607B1 (fr) * 1990-05-30 1992-08-28 Oreal Composition destinee a etre utilisee pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives d'alkyl-2 amino-4 (ou dialkyl-2-4) pyrimidine oxyde-3 .
JPH06509332A (ja) * 1991-07-05 1994-10-20 メルク シヤープ エンド ドーム リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
JPH06509090A (ja) * 1991-07-10 1994-10-13 メルク シヤープ エンド ドーム リミテツド 芳香族化合物、それらを含む組成物、及び治療におけるそれらの使用
GB9201179D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
DE4227203C2 (de) * 1992-08-17 1994-03-24 Kao Corp Gmbh Mittel und Verfahren zur Haarbehandlung
GB9222486D0 (en) * 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
CA2148256A1 (fr) * 1992-10-29 1994-05-11 Ralph M. Hart Compositions et methodes appropriees pour utilisation a des fins therapeutiques et pharmaceutiques
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1072355A (en) * 1964-06-17 1967-06-14 Michael Collin Antiseptic and anti-pruretic solution containing camphor
US3519711A (en) * 1967-09-01 1970-07-07 Robert E Svigals Composition and method of treating pruritic conditions of the skin
US4477439A (en) * 1981-04-13 1984-10-16 Walter J. Monacelli Treatment of irritated and excoriated areas around the stoma of ostomy patients
EP0217975A1 (fr) * 1985-10-08 1987-04-15 Psori-Med Ag Mélange de sels pour le traitement du psoriasis et autres maladies de la peau
US5296476A (en) * 1989-09-08 1994-03-22 Henderson Esther G Skin care compositions
EP0451300A1 (fr) * 1990-04-10 1991-10-16 Romuald Dr. Kowalski Composition contenant une dispersion colloidale de sulfate de baryum
DE4315866C1 (de) * 1993-05-12 1994-05-05 Wogepharm Gmbh Äußerliche Zubereitungen zur Therapie von Hauterkrankungen mit Photosensibilisatoren
WO1996019184A1 (fr) * 1994-12-21 1996-06-27 Cosmederm Technologies Formulations et procedes pour diminuer l'irritation de la peau
WO1996019228A1 (fr) * 1994-12-21 1996-06-27 Cosmederm Technologies Formulations et procedes pour diminuer l'irritation de la peau
WO1996019182A1 (fr) * 1994-12-21 1996-06-27 Cosmederm Technologies Formulations et procedes pour diminuer l'irritation de la peau

Also Published As

Publication number Publication date
EP0737471A2 (fr) 1996-10-16
US5851556A (en) 1998-12-22
CA2173689A1 (fr) 1996-10-11
NO323573B1 (no) 2007-06-11
NO961371L (no) 1996-10-11
CA2173689C (fr) 2003-10-14
NO961371D0 (no) 1996-04-03

Similar Documents

Publication Publication Date Title
EP0737471A3 (fr) Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
CA2167980A1 (fr) Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
CA2182030A1 (fr) Utilisation d'un antagoniste de bradykinine dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
NO20034751L (no) Antranilsyreamider, deres fremstilling og anvendelse samt preparater
DE69532751D1 (de) Kosmetische, pharmazeutische oder dermatologische Zusammensetzung, sowie die Zusammensetzung Alpha-TNFAntagonisten enthaltend
CA2172777A1 (fr) Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
DK0957900T3 (da) Sammensætninger og fremgangsmåder til topisk påföring af terapeutiske midler
GB2303629B (en) Hydroxamic acids and their use as metalloproteinase inhibitors
HUP0003583A2 (hu) Ibuprofen tartalmú gyógyászati szerek
TNSN98154A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant
EP0391002A3 (fr) Compositions pharmaceutiques contenant de l'acide anthranilique N-(3-4-diméthoxycinnamoyl)
ATE245429T1 (de) Antitrombotische mitteln
FR2856294B1 (fr) Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
CA2104677A1 (fr) Compositions pour administration topique contenant du propionate de fluticasone et de l'oxyconazole ou des sels d'oxyconazole
MA26725A1 (fr) Derives de resorcinol, compositions pharmaceutiques les contenant et procede pour leur preparation
BR0115883A (pt) Derivados de ácido amino-furan-2-il-acético e ácido amino-tien-2-il-acético substituìdos e seu emprego para o tratamento de cefaléia ou dor
JP3200187B2 (ja) チロシナーゼ活性阻害剤
WO2004018044A8 (fr) Usage therapeutique
FR2757391B1 (fr) Utilisation d'un extrait de la plante terminalia, dans les domaines cosmetique et pharmaceutique, notamment dermatologique
ATE168004T1 (de) Juckreizstillendes mittel
US20040023937A1 (en) Anti-cancer formulation
ATE223717T1 (de) Topisch anzuwendendes abschäumendes arzneimittel zur behandlung von durch pityrosporum ovale verursachten hauterkrankungen
PT876144E (pt) "agentes terapeuticos, contendo ebselen contra a asma"
JP2000044459A (ja) 皮膚外用剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE DE DK FR GB IE SE

17P Request for examination filed

Effective date: 19960912

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 7/48 A

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): BE DE DK FR GB IE SE

17Q First examination report despatched

Effective date: 20010921

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20031227